U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Form 8-K
Current
Report Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported):
April 13, 2020
SUNSHINE BIOPHARMA, INC.
(Exact
name of small business issuer as specified in its
charter)
|
Colorado
|
000-52898
|
20-5566275
|
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer ID No.)
|
6500 Trans-Canada Highway
4th Floor
Pointe-Claire, Quebec, Canada H9R 0A5
(Address
of principal executive offices)
514) 426-6161
(Issuer’s
Telephone Number)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
[ ]
Item
8.01 Other
Events.
Sunshine Biopharma, Inc..(“we,” “us,”
“our” or the “Company”) will be relying on
the Securities and Exchange Commission’s Order under Section
36 of the Securities Exchange Act of 1934 Granting Exemptions From
Specified Provisions of the Exchange Act and Certain Rules
Thereunder dated March 4, 2020 (Release No. 34-88318) (the
“Order”) to delay the filing of its Annual Report on
Form 10-K for the year ended December 31, 2019 (the “2019
10-K”) due to the circumstances related to COVID-19.We have a
small accounting staff based in Montreal, Canada and Denver,
Colorado both of which are subject to a citywide lockdown, which
is making it very difficult for us to complete the report in a
timely manner. Furthermore, our directors, consultants and
our auditors are all working remotely and are also on lockdown in
various jurisdictions due to coronavirus. Therefore, we require
extra time to complete our 10K for 2019.
Notwithstanding the foregoing, the Company expects to file the 2019
10-K no later than May 29, 2020 (which is 60 days from the 2019
10-K’s original filing deadline of March 30,
2020).
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Dated: April 13,
2020
|
SUNSHINE
BIOPHARMA, INC.
|
|
|
(Registrant)
|
|
|
|
|
|
By: /s/ Dr. Steve N.
Slilaty
|
|
|
Dr. Steve N.
Slilaty, Chief Executive Officer
|